Ultragenyx Pharmaceutical Receives Breakthrough Therapy Designation from FDA for GTX-102 in Treating Angelman Syndrome

Strategic Insights -

Ultragenyx Pharmaceutical Inc. has made a significant breakthrough in the treatment of Angelman syndrome after receiving Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its drug GTX-102 (apazunersen). This designation is a major milestone for the company, as it aims to expedite the development and review of GTX-102, which has shown promising results in treating patients with Angelman syndrome. According to the FDA, preliminary clinical evidence from a Phase 1/2 study in 74 patients (4-17 years of age) with a full maternal UBE3A gene deletion demonstrated rapid, sustained, and continuing improvements across multiple symptom domains when treated for up to three years.

Key Takeaways:

  • Ultragenyx Pharmaceutical Inc. has received Breakthrough Therapy Designation from the FDA for its drug GTX-102 (apazunersen) in treating Angelman syndrome.
  • The FDA's decision is based on preliminary clinical evidence from a Phase 1/2 study in 74 patients (4-17 years of age) with a full maternal UBE3A gene deletion.
  • The study showed significant improvements in multiple symptom domains in patients treated with GTX-102 for up to three years.
  • The Breakthrough Therapy Designation aims to expedite the development and review of GTX-102, a treatment for a serious or life-threatening disease.
  • Ultragenyx Pharmaceutical Inc. is committed to developing GTX-102 to improve the lives of patients with Angelman syndrome.
  • The company has also emphasized the importance of caution and the uncertainty associated with clinical drug development.

Statistics:

  • 74 patients participated in the Phase 1/2 study in the 4-17 age range with a full maternal UBE3A gene deletion.
  • GTX-102 demonstrated rapid, sustained, and continuing improvements across multiple symptom domains in up to 3 years of treatment.
  • The FDA has designated GTX-102 as a Breakthrough Therapy for treating Angelman syndrome.
  • According to the FDA, preliminary clinical evidence indicates that GTX-102 may demonstrate substantial improvement on one or more clinically significant endpoints over existing therapies.

Sources:

  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, June 27, 2025.
  • SEC filing, Ultragenyx Pharmaceutical Inc. Form 10-Q, filed May 7, 2025.